.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Fluoxetine hydrochloride; olanzapine - Generic Drug Details

« Back to Dashboard
Fluoxetine hydrochloride; olanzapine is the generic ingredient in two branded drugs marketed by Sandoz, Lilly, Teva Pharms, and Par Pharm, and is included in five NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

This ingredient has forty-six patent family members in twenty-five countries.

There are twenty-seven drug master file entries for fluoxetine hydrochloride; olanzapine. Five suppliers are listed for this compound.

Summary for Generic Name: fluoxetine hydrochloride; olanzapine

Tradenames:2
Patents:2
Applicants:4
NDAs:5
Drug Master File Entries: see list27
Suppliers / Packaging: see list5
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: fluoxetine hydrochloride; olanzapine

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-003Dec 24, 2003RXYes► subscribe► subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-003Dec 24, 2003RXYes6,960,577► subscribe ► subscribe
Teva Pharms
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL202074-001Mar 25, 2013RXNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fluoxetine hydrochloride; olanzapine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-001Apr 9, 20075,229,382*PED► subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-005Dec 24, 20035,229,382*PED► subscribe
Lilly
SYMBYAX
fluoxetine hydrochloride; olanzapine
CAPSULE;ORAL021520-002Dec 24, 2003522,982► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fluoxetine hydrochloride; olanzapine

Country Document Number Estimated Expiration
Australia725556► subscribe
Canada2250187► subscribe
Canada2332814► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc